Skip to main content
. 2023 Aug 2;11(6):101063. doi: 10.1016/j.gendis.2023.06.032

Table 2.

Clinical studies for the treatment of cisplatin resistance in ovarian cancer.

Type of regimen Therapy Research progress Treatment-related indicators
Reference
Progression-free survival (months) Overall survival (months) Objective response rate (%)
Platinum alternative drugs Carboplatin In clinic 4.8 127
Carboplatin, paclitaxel In clinic 12.5 7.4 126
Oxaliplatin In clinic 23.0 129
Paclitaxel In clinic 36.5 132
Paclitaxel, cisplatin In clinic 30.0 58.5 132
Paclitaxel, carboplatin In clinic 25.0 55.0 132
Topotecan In clinic 4.8 15.8 10.0 136
Pemetrexed Phase II clinical trial 2.9 11.4 21 139
Pemetrexed, carboplatin Phase II clinical trial 9.4 32.8 140
Gemcitabine In clinic 3.0 141
Topotecan, cisplatin In clinic 2.5 19.3 22.6 142
PLD (pegylated liposomal doxorubicin) In clinic 3.7 143
PLD, olaratumab Phase II clinical trial 5.5 143
Anti-angiogenic drugs Bevacizumab In clinic 4.4 145
Bevacizumab, gemcitabine In clinic 4 15.3 25.0 148
Ramucirumab Phase II clinical trial 3.2 10.0 149
Apatinib Phase Ⅳ clinical trial 5.0 9.5 151
Apatinib, etoposide Phase II clinical trial 5.6 10.3 36.4 150
PARP inhibitors Olaparib In clinic 2.9 17.9 156
Olaparib, PLD Phase II clinical trial 5.8 29.0 155
Niraparib Phase Ⅲ clinical trial 21.9 20.1 157
Rucaparib Phase Ⅲ clinical trial 16.6 158
Cell-cycle kinase inhibitors Ribociclib Phase I clinical trial 11.4 79.3 163
Abemaciclib Phase Ⅲ clinical trial 5.3 165
Abemaciclib, fulvestrant Phase Ⅲ clinical trial 16.9 46.7 165
Immunotherapy Nivolumab Phase II clinical trial 3.5 20.0 172
Nivolumab, ipilimumab Phase II clinical trial 3.9 28.1 31.4 174
Pembrolizumab Phase II clinical trial 2.1 7.4 176
Pembrolizumab, niraparib Phase I/II clinical trial 18.0 177
Pembrolizumab, PLD Phase II clinical trial 19.0 180
Pembrolizumab, bevacizumab, cyclophosphamide Phase II clinical trial 10.0 47.5 181
Pembrolizumab, cisplatin, gemcitabine Phase II clinical trial 6.2 11.3 60.0 182
Avelumab, PLD Phase Ⅲ clinical trial 3.7 15.7 183
Durvalumab, olaparib Phase II clinical trial 5.36 15.5 42.9 184